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Clinical Question 
What is the safest and most effective antidepressant therapy in pregnant women? 
Evidence-Based Answer 
Selective serotonin reuptake inhibitors (SSRIs) are considered first-line agents for the treatment 
of depression in pregnant women. SSRIs and tricyclic antidepressants (TCAs) are considered 
safe and effective in pregnant women, although some studies have indicated increased short-term 
neonatal adverse effects after exposure to antidepressants in the third trimester.1-6 [Strength of 
recommendation: B, based on cohort studies] 
SSRIs appear to have a more favorable side-effect profile than TCAs.7 [Strength of 
recommendation: B, based on extrapolation from a systematic review of randomized controlled 
trials (RCTs)] One small study8 supports the use of the phenethylamine agent venlafaxine 
(Effexor) in pregnant women. [Strength of recommendation: B, cohort study] 
Evidence Summary 
Decisions about which antidepressant to prescribe during pregnancy depend on assessments of 
efficacy and safety. Ethical considerations make randomized controlled trials of antidepressants 
during pregnancy impossible. Therefore, the best available evidence for assessing efficacy in 
pregnant women comes from an extrapolation of studies of nonpregnant women; for assessing 
safety, the best available evidence comes from prospective cohort studies. An analysis of 11 
double-blind RCTs found that the SSRI fluoxetine (Prozac) and TCAs significantly reduced 
symptoms of depression; fluoxetine had fewer side effects.7 
Studies assessing safety have measured rates of major malformations, spontaneous pregnancy 
loss, preterm delivery, neonatal toxicity, and adverse effects on childhood growth and 
development. The results of multiple studies have indicated no increased risk for major 
malformations when SSRIs or TCAs are used during pregnancy.1-4,8 
One meta-analysis1 of prospective controlled and uncontrolled cohort studies examined the risk 
of major fetal malformations after fluoxetine use during the first trimester of pregnancy and 
identified two controlled studies that involved approximately 350 women taking fluoxetine. For 
these two studies, the odds ratio was 1.33 (95 percent confidence interval [CI], 0.49 to 3.58), 
which was not significant. 
A second review2 of prospective controlled studies compared the effects of TCAs, fluoxetine, 
and newer SSRIs in approximately 625 pregnant women and found no significant difference in 
the rate of major fetal malformations. However, the review did find one study that reported a 
significantly higher rate of three or more minor anomalies in infants of women who took 
fluoxetine during the first trimester compared with women who did not take fluoxetine 
(15.5 versus 6.5 percent). There was no pattern to the anomalies.2 The number needed to harm 
was 11 (95 percent CI, 6 to 86). 
A multicenter, prospective, controlled study8 compared 150 women who took venlafaxine, 150 
women who took SSRIs, and 150 women who took nonteratogens. This study also found no 
difference in the rate of major malformations in infants of women taking antidepressants 
compared with those taking nonteratogens. 
Results of studies evaluating the effect of antidepressants on pregnancies and on neonates in the 
immediate postpartum period have been mixed but, overall, reassuring. Rates of spontaneous 
pregnancy loss in women who took fluoxetine, TCAs, newer SSRIs, or venlafaxine were not 
significantly different compared with rates in control groups.2,8 While one study found an 
increased rate of preterm delivery in 70 women who took fluoxetine during the third trimester 
compared with a group of women who took fluoxetine before the 25th week of gestation 
(relative risk = 4.8; 95 percent CI, 1.1 to 20.8), other studies that included SSRI use during the 
third trimester reported no difference in gestational age or birth weight among the infants.2,4,5 
Neonatal toxicity (e.g., jitteriness, respiratory distress, admission to a special care nursery) has 
been noted in studies of women taking TCAs through delivery and in one study of third-trimester 
fluoxetine use. However, neonatal toxicity was not consistently reported in all studies.2 A recent, 
large, prospective study6 of 997 infants whose mothers took antidepressants during late 
pregnancy reported increased risks for preterm birth (odds ratio = 1.96; 95 percent CI, 1.6 to 
2.41) and adverse short-term neonatal effects. These results were slightly more pronounced in 
cases of TCA use than in cases of SSRI use. 
Data on long-term neurodevelopment in children exposed to antidepressants in utero are limited 
but reassuring. Fifty-five children exposed to fluoxetine and 80 children exposed to TCAs were 
compared with a control group of 84 children. There were no significant differences in IQ scores 
or development in language or behavior.2 More than one third of the women had continued 
antidepressant therapy throughout their pregnancy. 
Recommendations from Others 
A pediatric advisory subcommittee of the U.S. Food and Drug Administration recently suggested 
labeling changes for SSRIs and venlafaxine to inform patients and physicians of reports of 
neonatal toxicity and neonatal withdrawal syndrome associated with exposure to antidepressants 
during the third trimester. The labeling changes state that physicians should carefully consider 
the potential risks and benefits of therapy when treating a pregnant woman with depression. The 
American College of Obstetricians and Gynecologists does not have a guideline on the use of 
antidepressants in pregnant women. 
Clinical Commentary 
Depression affects approximately 10 percent of pregnant women. Although antidepressants 
appear to be safe and effective when used during pregnancy, the decision to continue or begin 
antidepressant therapy in a pregnant woman is complicated. Patients and their physicians must 
weigh the potential harm from depression to both mother and child against the possible neonatal 
and long-term effects from fetal exposure to antidepressants. Factors to consider include the 
severity of the depression, the availability and efficacy of nonpharmacologic treatments, past 
experience with specific medications, and whether to continue medication use throughout the 
entire pregnancy. Fortunately, data from cohort studies regarding safety for both SSRIs and 
TCAs are reassuring.  
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